CytoDyn Inc. (OTCMKTS:CYDY) Sees Significant Growth in Short Interest

CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) saw a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 10,797,300 shares, a growth of 25.3% from the July 31st total of 8,617,700 shares. Based on an average trading volume of 6,688,300 shares, the short-interest ratio is presently 1.6 days.

CytoDyn Stock Up 6.8 %

OTCMKTS CYDY traded up $0.01 on Friday, reaching $0.15. The company had a trading volume of 1,971,628 shares, compared to its average volume of 2,554,844. CytoDyn has a 52 week low of $0.11 and a 52 week high of $0.42. The stock's 50 day moving average is $0.14 and its 200-day moving average is $0.16. The stock has a market cap of $158.27 million, a price-to-earnings ratio of -2.80 and a beta of 0.15.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.